Cloud Based Contact Center Software Is Fastest Growing Segment Fueling The Growth Of Insulin Sensitizers Market
 |
| Insulin Sensitizers Market |
The global Insulin Sensitizers Market is estimated to be valued at US$ 15.09 Bn in 2023 and is expected to exhibit a CAGR of 5.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Insulin sensitizers are medicines that help the body respond better to insulin. They help control blood sugar levels in patients with type 2 diabetes by making cells more sensitive to the blood sugar-lowering effects of insulin. They play a vital role in controlling blood sugar levels without causing weight gain or hypoglycemia.
Market key trends:
There is increasing demand for combination therapies in diabetes treatment. Combining multiple diabetic medicines such as insulin sensitizers with other oral anti-diabetes drugs is becoming a preferred treatment option. This is because combination therapies help improve glycemic control more effectively than monotherapy. For example, combining an insulin sensitizer with an SGLT2 inhibitor or DPP-4 inhibitor provides enhanced blood sugar lowering along with other health benefits like weight loss.
Segment Analysis
The global insulin sensitizers market can be segmented based on drug, route of administration, distribution channel, and geography. By drug, the market is dominated by biguanides, which account for over 50% revenue share. Biguanides such as metformin are first-line treatment choices for managing type 2 diabetes as they help reduce blood sugar levels with low side effects. Several clinical studies have demonstrated metformin's effectiveness in reducing HbA1c levels and weight loss.
Key Takeaways
The Global Insulin Sensitizers Market Demand is expected to witness high growth, exhibiting CAGR of 5.5% over the forecast period, due to increasing prevalence of diabetes. The global market size for insulin sensitisers is expected to reach US$ 15.09 Bn by 2023.
Regional analysis - North America dominates the global market with over 30% revenue share due to rapid uptake of new drugs and presence of major players. Asia Pacific follows North America and is expected to witness fastest growth owing to rising health awareness, increasing disposable incomes, and growing base of patients with diabetes in China and India.
Key players operating in the insulin sensitisers market include Eli Lilly and Company, Novo Nordisk, Sanofi, Merck & Co., Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, and Takeda Pharmaceutical. Eli Lilly and Company leads the market with its extensive portfolio of diabetes drugs including Trulicity and others. Novo Nordisk and Sanofi hold second and third position respectively with their prominent brands such as Victoza, Levemir, and Lantus.
Explorer more information on this topic, Please visit-
Comments
Post a Comment